Yesterday I flew to Switzerland for the day, to gage what was going on at the 9th Annual Sachs conference for European Biotech CEOs. Here I had the chance to Interview Cambridge UK’s Mission Therapeutics on investment and technology..
Panel discussions covered Partnering and Investment for various therapeutic platforms – in MedTech, Diagnostics and generally ‘Israel’ (and I assume the growing Biotech scene there).
I had the opportunity to meet Anker Lundemose, the CEO of Mission Therapeutics, from just outside of Cambridge (UK). Founded in 2011, Mission Therapeutics, a private drug discovery company which aims to commercialize highly expert research towards the treatment of cancer and other diseases via the ubiquitin cell signalling pathway.
A nice chat to get his comment on this round as well as his plan for the future of the development of the platform.